|
Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival. |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Immutep; Janssen-Cilag; Lilly; Merck; MorphoSys; Novartis; Regeneron; Roche; SERVIER; Tesaro |
|
|
Honoraria - Merck Serono; SERVIER |
Travel, Accommodations, Expenses - SERVIER |
|
|
Research Funding - Amgen; Celgene; Lilly; Merck KGaA; Nordic Drugs; Roche; SERVIER; Taiho Pharmaceutical |
|
|
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER |
Research Funding - Bayer; SERVIER |
Travel, Accommodations, Expenses - Amgen; Bayer; Roche; SERVIER |
|
|
Consulting or Advisory Role - Roche; Sanofi; SERVIER |
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer (Inst); Nordic Bioscience (Inst) |
Travel, Accommodations, Expenses - Nordic Bioscience |
|
|
Research Funding - SERVIER |
|
|
No Relationships to Disclose |
|
|
Research Funding - SERVIER |
|
|
Research Funding - SERVIER |
|
|
Consulting or Advisory Role - Amgen; Merck Serono; Roche; Sanofi; SERVIER |
Speakers' Bureau - Amgen; Merck Serono; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Merck Serono; Roche |
|
|
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Incyte; Merck KGaA; Roche/Genentech; Servier; Sirtex Medical; Zymeworks |
Consulting or Advisory Role - Bayer; ERYTECH Pharma; Incyte; Pfizer; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical |
Speakers' Bureau - Celgene; Incyte; Merck KGaA; SERVIER; Sirtex Medical |
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst) |
|
|
Honoraria - Amgen; Lilly; Merck; Roche; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Merck; Roche; SERVIER |
Research Funding - Amgen (Inst); Bayer (Inst); Merck (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst) |
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Roche; SERVIER |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Research Funding - SERVIER |